Financial Enhancement Group LLC Makes New $6.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)

Financial Enhancement Group LLC bought a new position in United Therapeutics Co. (NASDAQ:UTHR) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 18,616 shares of the biotechnology company’s stock, valued at approximately $6,671,000. United Therapeutics accounts for 1.2% of Financial Enhancement Group LLC’s holdings, making the stock its 27th biggest holding.

A number of other hedge funds and other institutional investors have also made changes to their positions in UTHR. ClariVest Asset Management LLC lifted its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the period. V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics in the 2nd quarter valued at about $30,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter worth approximately $33,000. USA Financial Formulas bought a new position in shares of United Therapeutics during the third quarter valued at approximately $33,000. Finally, Values First Advisors Inc. purchased a new position in United Therapeutics during the third quarter valued at approximately $90,000. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on UTHR shares. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Argus boosted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company raised their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. Finally, HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $370.86.

Insiders Place Their Bets

In other news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now owns 3,675 shares in the company, valued at $1,384,115.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 81,422 shares of company stock valued at $29,229,828. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Up 3.8 %

Shares of NASDAQ UTHR opened at $397.49 on Thursday. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $399.23. The firm has a market cap of $17.75 billion, a P/E ratio of 17.46, a P/E/G ratio of 1.08 and a beta of 0.56. The business’s 50 day moving average price is $357.42 and its 200 day moving average price is $320.37.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.38 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 25.57 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.